Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00362882 · ClinicalTrials.gov registry record · Phase 2
Docetaxel and Bortezomib in Treating Patients With Progressive or Recurrent Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 81
- Enrollment target
NCT00362882: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00362882 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 81 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00362882, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 81 participants
- Enrollment target
Study Summary
This trial is studying two different schedules of docetaxel and bortezomib to compare how well they work in treating patients with progressive or recurrent non-small cell lung cancer. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving docetaxel together with bortezomib may kill more tumor cells
Interventions
- OTHER laboratory biomarker analysis
- DRUG docetaxel
- OTHER immunohistochemistry staining method
- DRUG bortezomib
- OTHER immunoenzyme technique
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2006-07 |
| Est. Completion | 2010-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00362882
The ClinicalTrials.gov registry entry for NCT00362882 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 81 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT00362882 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00362882 about?
NCT00362882 is a clinical study titled "Docetaxel and Bortezomib in Treating Patients With Progressive or Recurrent Non-Small Cell Lung Cancer". This trial is studying two different schedules of docetaxel and bortezomib to compare how well they work in treating patients with progressive or recurrent non-small cell lung cancer. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by k...
What is the current status of trial NCT00362882?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 81 participants. The study started on 2006-07. Estimated completion is 2010-07.
What interventions are being tested in trial NCT00362882?
The interventions under investigation include: laboratory biomarker analysis (OTHER), docetaxel (DRUG), immunohistochemistry staining method (OTHER), bortezomib (DRUG), immunoenzyme technique (OTHER).
Who is sponsoring clinical trial NCT00362882?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.